Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375229 | PMC |
| http://dx.doi.org/10.1093/ndtplus/sfm022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial Intelligence in Nephrology: Clinical Applications and Challenges.
Kidney Med
January 2025
Division of Nephrology, Florida State University School of Medicine, Tallahassee, FL.
Artificial intelligence (AI) is increasingly used in many medical specialties. However, nephrology has lagged in adopting and incorporating machine learning techniques. Nephrology is well positioned to capitalize on the benefits of AI.
View Article and Find Full Text PDFGenetic Assessment of Living Kidney Transplant Donors: A Survey of Canadian Practices.
Can J Kidney Health Dis
January 2025
Multiorgan Transplant Program, Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Background: Kidney failure is a prevalent condition with tendency for familial clustering in up to 27% of the affected individuals. Living kidney donor (LKD) transplantation is the optimal treatment option; however, in Canada, more than 45% of LKDs are biologically related to their recipients which subjects recipients to worse graft survival and donors to higher future risk of kidney failure. Although not fully understood, this observation could be partially explained by genetic predisposition to kidney diseases.
View Article and Find Full Text PDFClinical management of female patients with Fabry disease based on expert consensus.
Orphanet J Rare Dis
January 2025
Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Fabry disease is an X-linked lysosomal storage disorder that causes accumulation of glycosphingolipids in body tissues and fluids, leading to progressive organ damage and life-threatening complications. It can affect both males and females and can be classified into classic or later-onset phenotypes. The disease severity in females ranges from asymptomatic to the more severe, classic phenotype.
View Article and Find Full Text PDFSodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series.
Intern Med J
December 2024
Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Background: Fabry disease is a rare X-linked multisystem disease, with progressive proteinuric kidney disease contributing significantly to morbidity and mortality of these patients. Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kidney disease.
Aim: Evaluate the effects of SGLT2I on kidney function and albuminuria in patients with Fabry disease.
Epidemiology and early predictors of Fabry nephropathy: evaluation of long-term outcomes from a national Fabry centre.
J Nephrol
December 2024
The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.
Article Synopsis
- Fabry disease can lead to chronic kidney disease (CKD) due to accumulated sphingolipids causing kidney damage, impacting treatment and prognostic planning.
- In a study of 405 Fabry patients, significant findings included that 60.5% received treatments, 29.7% had cardiovascular events, and 3.3% reached end-stage kidney disease (ESKD), with men facing higher risks.
- Key indicators for CKD development included older age, history of cardiovascular issues, specific medication use, and higher urine albumin-to-creatinine ratios, highlighting the need for monitoring even in patients with normal kidney function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!